Cargando…
Impairment of endoxifen formation in tamoxifen‐treated premenopausal breast cancer patients carrying reduced‐function CYP2D6 alleles
AIMS: Tamoxifen is bioactivated to endoxifen by polymorphic CYP2D6‐dependent metabolism. Here, endoxifen levels were compared to CYP2D6 diplotypes, tentative target concentrations and side effects. METHODS: In total, 118 Swedish premenopausal breast cancer patients diagnosed 2006–2014, with on‐going...
Autores principales: | Thorén, Linda, Lindh, Jonatan D., Ackehed, Gerd, Kringen, Marianne Kristiansen, Hall, Per, Bergh, Jonas, Molden, Espen, Margolin, Sara, Eliasson, Erik |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9328423/ https://www.ncbi.nlm.nih.gov/pubmed/32713032 http://dx.doi.org/10.1111/bcp.14500 |
Ejemplares similares
-
Impact of systemic adjuvant therapy and CYP2D6 activity on mammographic density in a cohort of tamoxifen-treated breast cancer patients
por: Thorén, Linda, et al.
Publicado: (2021) -
Prediction of CYP2D6 poor metabolizers by measurements of solanidine and metabolites—a study in 839 patients with known CYP2D6 genotype
por: Wollmann, Birgit M., et al.
Publicado: (2023) -
Impact of the novel CYP2C:TG haplotype and CYP2B6 variants on sertraline exposure in a large patient population
por: Bråten, Line Skute, et al.
Publicado: (2022) -
Adherence to endocrine therapy in early breast cancer in relation to Cytochrome P450 2D6 genotype: a comparison between pharmacy dispensation data and medical records
por: Thorén, Linda, et al.
Publicado: (2023) -
Simplified phenotyping of CYP2D6 for tamoxifen treatment using the N-desmethyl-tamoxifen/ endoxifen ratio
por: Lee, Clara Inkyung, et al.
Publicado: (2020)